Physician profile
Jared S Ankerman
NPI 1538519764
$1,666.34
in general payments reported to CMS, 2019-2025
21 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $83.96 · 2023: $703 · 2024: $453 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $333.74 | 2023-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $207.68 | 2022-2025 | Farxiga |
| Novo Nordisk INC | $154.77 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $143.61 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $132.80 | 2023-2025 | |
| Ethicon INC. | $130.59 | 2023 | Monarch Platform |
| Astellas Pharma US INC | $105.90 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.56 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $82.20 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $71.25 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.51 | 2022-2024 | Trulance, Xifaxan |
| Dexcom, INC. | $26.23 | 2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $19.18 | 2023 | Quviviq |
| Amgen INC. | $18.63 | 2025 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $17.93 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $14.95 | 2023 | Ajovy |
| Exeltis, USA INC. | $14.64 | 2024 | Slynd |
| Janssen Pharmaceuticals, INC | $13.87 | 2024 | Xarelto |
| Noven Therapeutics, LLC | $13.30 | 2024 | Xelstrym |
| Sanofi-Aventis U.S. LLC | $13.08 | 2022 | |
| Philips North America LLC | $12.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Ankerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.